Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Therapeutic target tailored chemotherapy-Grupo Hospital de Madrid-rectal cancer
- Development stage
- Unknown
- Lead developer
- HM Hospitals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Therapeutic target tailored chemotherapy-Grupo Hospital de Madrid-rectal cancer is a personalized neoadjuvant treatment protocol designed for patients with localized rectal carcinoma. Developed by Grupo Hospital de Madrid, the regimen utilizes a backbone of capecitabine (an antimetabolite) in combination with intensity-modulated radiotherapy (IMRT). The addition of further cytotoxic or targeted agents is tailored to the individual tumor's molecular profile: irinotecan is included for Topoisomerase-1 positive tumors, oxaliplatin for Topoisomerase-1 negative and ERCC-1 negative tumors, and either bevacizumab or cetuximab is selected based on K-Ras and B-Raf mutation status. This precision medicine approach aims to optimize the pathological complete response rate and improve long-term disease-free survival by matching the chemotherapy components to specific therapeutic targets.
- Other names
- Therapeutic target tailored chemotherapyTT-tailored chemotherapyTailored Chemotherapy and IMRT in Rectal Carcinoma
02
Targets
DNATOP1 (DNA Topoisomerase I)EGFR (Epidermal growth factor receptor)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on Therapeutic target tailored chemotherapy-Grupo Hospital de Madrid-rectal cancer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Therapeutic target tailored chemotherapy-Grupo Hospital de Madrid-rectal cancer.